Direct HGH administration bypasses the body's own regulatory signals entirely, delivering the hormone itself straight into circulation. A GHRH analog like Tesamorelin instead works one step earlier in the axis, mimicking the natural hypothalamic signal that tells the pituitary gland to secrete growth hormone.
This means Tesamorelin stimulates the body's own production pathway rather than replacing it, a mechanistically distinct approach from direct hormone replacement, studied in its own dedicated body of research literature.
This upstream mechanism is part of why Tesamorelin, an unscheduled research peptide, sits in a different regulatory category from HGH, a prescription pharmaceutical, across many jurisdictions including how each is treated for research-chemical or drug distribution purposes.
REVIVE LAB UAE supplies Tesamorelin as a research peptide for laboratory use; it does not supply, and makes no equivalence claim to, direct HGH. The two compounds occupy entirely separate positions both mechanistically and regulatorily.
Because GHRH analogs work by stimulating the pituitary, their mechanism depends on a functioning pituitary gland capable of responding to that stimulus. Direct HGH administration has no such dependency, since it supplies the hormone itself rather than relying on the body to produce it.
This dependency is a defining feature researchers consider when interpreting studies on GHRH analogs, since the pituitary's baseline capacity is a variable that direct HGH studies simply do not have to account for.
This is a mechanistic research comparison only, not a therapeutic recommendation, equivalence claim, or dosing guidance for either compound. Researchers working with Tesamorelin should consult REVIVE LAB UAE's product documentation and Certificate of Analysis for that specific peptide.
REVIVE LAB UAE does not sell HGH and this article does not describe or facilitate a purchase of it in any form.